.
17 mayo 2018
PharmaMar Announces Data Presentations For Both Its Molecules Yondelis® , Aplidin Overall survival (OS) results of randomized phase III study (ADMYRE trial) and Lurbinectedin at ASCO 2018 .
Entrada más reciente
Entrada antigua
Inicio